standard of care in COVID-19 mild to moderate - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias death D28detailed results GS-US-540-5774, 10 days, 2020 (REV) 1.29 [0.29; 5.85]
GS-US-540-5774, 5 days, 2020 (REV) 1.93 [0.35; 10.65]
1.54 [0.50 ; 4.78 ] GS-US-540-5774, 10 days, 2020 (REV), GS-US-540-5774, 5 days, 2020 (REV) 2 0% 784 moderate not evaluable deathsdetailed results GS-US-540-5774, 10 days, 2020 (REV) 1.32 [0.29; 5.88]
GS-US-540-5774, 5 days, 2020 (REV) 1.96 [0.35; 10.94]
1.56 [0.51 ; 4.83 ] GS-US-540-5774, 10 days, 2020 (REV), GS-US-540-5774, 5 days, 2020 (REV) 2 0% 796 moderate not evaluable deaths (time to event analysis only)detailed results GS-US-540-5774, 10 days, 2020 (REV) 1.32 [0.29; 5.88]
GS-US-540-5774, 5 days, 2020 (REV) 1.96 [0.35; 10.94]
1.56 [0.51 ; 4.83 ] GS-US-540-5774, 10 days, 2020 (REV), GS-US-540-5774, 5 days, 2020 (REV) 2 0% 796 moderate not evaluable clinical improvementdetailed results GS-US-540-5774, 10 days, 2020 (REV) 0.86 [0.57; 1.30]
GS-US-540-5774, 5 days, 2020 (REV) 0.61 [0.40; 0.91]
0.72 [0.51 ; 1.02 ] GS-US-540-5774, 10 days, 2020 (REV), GS-US-540-5774, 5 days, 2020 (REV) 2 30% 796 moderate not evaluable clinical improvement (14-day)detailed results GS-US-540-5774, 10 days, 2020 (REV) 0.63 [0.40; 0.99]
GS-US-540-5774, 5 days, 2020 (REV) 0.64 [0.41; 1.00]
0.64 [0.46 ; 0.87 ] GS-US-540-5774, 10 days, 2020 (REV), GS-US-540-5774, 5 days, 2020 (REV) 2 0% 784 moderate not evaluable clinical improvement (28-day)detailed results GS-US-540-5774, 10 days, 2020 (REV) 0.53 [0.29; 0.97]
GS-US-540-5774, 5 days, 2020 (REV) 0.57 [0.32; 1.03]
0.55 [0.36 ; 0.84 ] GS-US-540-5774, 10 days, 2020 (REV), GS-US-540-5774, 5 days, 2020 (REV) 2 0% 784 moderate not evaluable clinical improvement (7-day)detailed results GS-US-540-5774, 10 days, 2020 (REV) 0.97 [0.66; 1.45]
GS-US-540-5774, 5 days, 2020 (REV) 0.71 [0.48; 1.06]
0.83 [0.61 ; 1.13 ] GS-US-540-5774, 10 days, 2020 (REV), GS-US-540-5774, 5 days, 2020 (REV) 2 17% 784 moderate not evaluable clinical improvement (time to event analysis only)detailed results GS-US-540-5774, 10 days, 2020 (REV) 0.86 [0.70; 1.07]
GS-US-540-5774, 5 days, 2020 (REV) 0.87 [0.70; 1.07]
0.87 [0.74 ; 1.01 ] GS-US-540-5774, 10 days, 2020 (REV), GS-US-540-5774, 5 days, 2020 (REV) 2 0% 796 moderate not evaluable mechanical ventilationdetailed results GS-US-540-5774, 10 days, 2020 (REV) 3.92 [0.43; 35.38]
GS-US-540-5774, 5 days, 2020 (REV) 7.78 [0.41; 148.08]
5.01 [0.86 ; 29.20 ] GS-US-540-5774, 10 days, 2020 (REV), GS-US-540-5774, 5 days, 2020 (REV) 2 0% 784 moderate not evaluable recoverydetailed results GS-US-540-5774, 10 days, 2020 (REV) 0.90 [0.73; 1.11]
GS-US-540-5774, 5 days, 2020 (REV) 0.85 [0.69; 1.04]
0.87 [0.75 ; 1.01 ] GS-US-540-5774, 10 days, 2020 (REV), GS-US-540-5774, 5 days, 2020 (REV) 2 0% 796 moderate not evaluable serious adverse eventsdetailed results GS-US-540-5774, 10 days, 2020 (REV) 1.81 [0.81; 4.03]
GS-US-540-5774, 5 days, 2020 (REV) 2.00 [0.88; 4.57]
1.90 [1.07 ; 3.37 ] GS-US-540-5774, 10 days, 2020 (REV), GS-US-540-5774, 5 days, 2020 (REV) 2 0% 784 moderate not evaluable adverse eventsdetailed results GS-US-540-5774, 10 days, 2020 (REV) 0.62 [0.41; 0.92]
GS-US-540-5774, 5 days, 2020 (REV) 0.82 [0.55; 1.23]
0.71 [0.53 ; 0.95 ] GS-US-540-5774, 10 days, 2020 (REV), GS-US-540-5774, 5 days, 2020 (REV) 2 4% 784 moderate not evaluable 0.2 10.0 1.0 relative treatment effect www.metaEvidence.org 2024-05-17 09:18 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
